Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients.
Schizophrenia is a multifactorial disease in both clinical and molecular terms. Thus, depicting the molecular aspects of the disease will contribute to the understanding of its biochemical mechanisms and consequently may lead to the development of new treatment strategies. The protein phosphorylation/dephosphorylation switch acts as the main mechanism for regulating cellular signaling. Moreover, approximately onethird of human proteins are phosphorylable. Thus, identifying proteins differentially phosphorylated in schizophrenia postmortem brains may improve our understanding of the molecular basis of brain function in this disease. Hence, we quantified the phosphoproteome of corpus callosum samples collected post mortem from schizophrenia patients and healthy controls. We used state-of-the-art, bottom-up shotgun mass spectrometry in a two-dimensional liquid chromatography-tandem mass spectrometry setup in the MSE mode with label-free quantification. We identified 60,634 peptides, belonging to 3283 proteins. Of these, 68 proteins were differentially phosphorylated, and 56 were differentially expressed. These proteins are mostly involved in signaling pathways, such as ephrin B and ciliary neurotrophic factor signaling. The data presented here are novel because this was the very first phosphoproteome analysis of schizophrenia brains. They support the important role of glial cells, especially astrocytes, in schizophrenia and help to further the understanding of the molecular aspects of this disease. Our findings indicate a need for further studies on cell signaling, which might shape the development of treatment strategies.
Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Verônica M
VM
Saia-Cereda
Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Juliana S
JS
Cassoli
Laboratório de Neurociências (LIM-27), Instituto de Psiquiatria, Universidade de São Paulo, São Paulo, Brazil; Department of Psychiatry and Psychotherapy, Ludwig Maximilian University (LMU), Munich, Germany.
Andrea
A
Schmitt
Department of Psychiatry and Psychotherapy, Ludwig Maximilian University (LMU), Munich, Germany.
Peter
P
Falkai
Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil; Laboratório de Neurociências (LIM-27), Instituto de Psiquiatria, Universidade de São Paulo, São Paulo, Brazil; UNICAMP's Neurobiology Center, Campinas, Brazil. Electronic address: dmsouza@unicamp.br.
Daniel
D
Martins-de-Souza
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002853:Chromatography, Liquid; D002908:Chronic Disease; D003337:Corpus Callosum / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010766:Phosphorylation; D020543:Proteome; D040901:Proteomics; D012559:Schizophrenia / Q000378:metabolism*; D053719:Tandem Mass Spectrometry
D020543:Proteome
Corpus callosum; Phosphoproteome; Phosphoproteomics; Proteome; Proteomics; Schizophrenia